Precision Oncology Solutions: Development and validation of NGS assays
Liquid Biopsy: Developing assays to detect oncogenic markers in blood plasma for upfront cancer diagnosis, prognosis, and treatment.
Public Health Integration: Validating NGS methodology for diagnosing actionable molecular alterations in lung cancer for the Chilean public health system, including comprehensive cost documentation.
Pan-Cancer Studies: Characterization of tumors in South American patients to uncover novel driver mutations in actionable genes
Chilean Genetic Landscape: Studying the genetic variation of the Chilean population and its specific impact on the diagnosis of somatic mutations.
Target Discovery: Discovery and validation of novel driver mutations in actionable genes.
Resistance Mechanisms: Discovering and understanding resistance to cancer treatment
RNA Editing in Oncology: Investigating how Adenosine Deaminase RNA Specific (ADAR) regulates drug response in breast cancer.
Advanced Breast Cancer: Identifying novel mechanisms and biomarkers predicting therapy response.
OncoValor-AI: Integrating Artificial Intelligence with molecular data to optimize the clinical value and cost-effectiveness of precision oncology in the Chilean healthcare ecosystem.
Predictive Analytics: Developing AI-driven models to enhance the interpretation of NGS data and improve patient stratification for targeted therapies.